MyBCTeam

It sounds like you might be asking about T-DM1, also known as Kadcyla (ado-trastuzumab emtansine). It's a targeted therapy used for HER2-positive early breast cancer.

Here's how it works:

- It's an antibody-drug conjugate, meaning it combines a targeted therapy (trastuzumab/Herceptin) with a chemotherapy drug (emtansine) Show Full Answer

It sounds like you might be asking about T-DM1, also known as Kadcyla (ado-trastuzumab emtansine). It's a targeted therapy used for HER2-positive early breast cancer.

Here's how it works:

- It's an antibody-drug conjugate, meaning it combines a targeted therapy (trastuzumab/Herceptin) with a chemotherapy drug (emtansine)
- This combination delivers chemotherapy directly to breast cancer cells
- This helps reduce damage to healthy tissue compared to traditional chemo

It's typically used for people with HER2-positive early breast cancer who still had signs of cancer after initial treatment with chemotherapy and HER2-targeted therapy.

Long-term study results are encouraging — 89.1% of people who received T-DM1 were alive after seven years, compared to 84.4% of those treated with trastuzumab alone.

As always, your oncologist is the best person to talk to about whether this treatment is right for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Kadcyle Extends Survival for Early HER2-Positive Breast Cancer